Clozapine-induced, dilated cardiomyopathy: a case report

Longhi, Sarah; Heres, Stephan

doi:10.1186/s13104-017-2679-5

Cited by 19 publications

(9 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…178 The clinical manifestations of clozapine-induced cardiomyopathy range from subclinical forms to severe ones with fulminant pulmonary edema and cardiogenic shock. 179,180 Often the symptoms are insidious and include persistent tachycardia at rest, palpitations, arrhythmias, dyspnea, chest pain, malaise and other signs and symptoms that may be underestimated by the clinicians until the symptoms resemble the clinical picture of heart failure or myocardial infarction. 181 Myocarditis is an uncommon, dose-independent, life-threatening adverse effect and occurs in up to 3% of treated patients.…”

Section: Uncommon Adverse Effectsmentioning

confidence: 99%

Safety of antipsychotics for the treatment of schizophrenia: a focus on the adverse effects of clozapine

Berardis¹,

Rapini²,

Olivieri³

et al. 2018

Therapeutic Advances in Drug Safety

156

125

View full text Add to dashboard Cite

Clozapine, a dibenzodiazepine developed in 1961, is a multireceptorial atypical antipsychotic approved for the treatment of resistant schizophrenia. Since its introduction, it has remained the drug of choice in treatment-resistant schizophrenia, despite a wide range of adverse effects, as it is a very effective drug in everyday clinical practice. However, clozapine is not considered as a top-of-the-line treatment because it may often be difficult for some patients to tolerate as some adverse effects can be particularly bothersome (i.e. sedation, weight gain, sialorrhea etc.) and it has some other potentially dangerous and life-threatening side effects (i.e. myocarditis, seizures, agranulocytosis or granulocytopenia, gastrointestinal hypomotility etc.). As poor treatment adherence in patients with resistant schizophrenia may increase the risk of a psychotic relapse, which may further lead to impaired social and cognitive functioning, psychiatric hospitalizations and increased treatment costs, clozapine adverse effects are a common reason for discontinuing this medication. Therefore, every effort should be made to monitor and minimize these adverse effects in order to improve their early detection and management. The aim of this paper is to briefly summarize and provide an update on major clozapine adverse effects, especially focusing on those that are severe and potentially life threatening, even if most of the latter are relatively uncommon.

show abstract

Section: Uncommon Adverse Effectsmentioning

confidence: 99%

Safety of antipsychotics for the treatment of schizophrenia: a focus on the adverse effects of clozapine

Berardis¹,

Rapini²,

Olivieri³

et al. 2018

Therapeutic Advances in Drug Safety

156

125

View full text Add to dashboard Cite

show abstract

“…41 In other detailed case reports, the use of clozapine as treatment for SP finally led to DCM. 42 , 43 , 44 This implies that SP and DCM may share biological pathways and that the treatment may target the process that is important to both.…”

Section: Resultsmentioning

confidence: 99%

Explaining the Genetic Causality for Complex Phenotype via Deep Association Kernel Learning

Bao

Deng

et al. 2020

Patterns

View full text Add to dashboard Cite

Summary The genetic effect explains the causality from genetic mutations to the development of complex diseases. Existing genome-wide association study (GWAS) approaches are always built under a linear assumption, restricting their generalization in dissecting complicated causality such as the recessive genetic effect. Therefore, a sophisticated and general GWAS model that can work with different types of genetic effects is highly desired. Here, we introduce a deep association kernel learning (DAK) model to enable automatic causal genotype encoding for GWAS at pathway level. DAK can detect both common and rare variants with complicated genetic effects where existing approaches fail. When applied to four real-world GWAS datasets including cancers and schizophrenia, our DAK discovered potential casual pathways, including the association between dilated cardiomyopathy pathway and schizophrenia.

show abstract

“…However, one clinical investigation has shown that after neuroleptics of SP, patients had a significantly increased possibility to get DCM 37 . In other detailed case reports, the usage of clozapine as the treatment to SP finally lead to DCM [38][39][40] . This implies that SP and DCM may share biological pathways and the treatment may target at the process that is important to both.…”

Section: Applications To Real Datasetsmentioning

confidence: 95%

Explaining the genetic causality for complex diseasesviadeep association kernel learning

Bao

Deng

et al. 2019

Preprint

View full text Add to dashboard Cite

The genetic effect explains the causality from genetic mutation to the development of complex diseases. Existing genome-wide association study (GWAS) approaches are always built under a linear assumption, restricting their generalization in dissecting complicated causality such as the recessive genetic effect. Therefore, a sophisticated and general GWAS model that can work with different types of genetic effects is highly desired. Here, we introduce a Deep Association Kernel learning (DAK) model to enable automatic causal genotype encoding for GWAS at pathway level. DAK can detect both common and rare variants with complicated genetic effects that existing approaches fail. When applied to real-world GWAS data, our approach discovered potential casual pathways that could be explained by alternative biological studies.

show abstract

Clozapine-induced, dilated cardiomyopathy: a case report

Cited by 19 publications

References 12 publications

Safety of antipsychotics for the treatment of schizophrenia: a focus on the adverse effects of clozapine

Safety of antipsychotics for the treatment of schizophrenia: a focus on the adverse effects of clozapine

Explaining the Genetic Causality for Complex Phenotype via Deep Association Kernel Learning

Explaining the genetic causality for complex diseasesviadeep association kernel learning

Contact Info

Product

Resources

About